470 related articles for article (PubMed ID: 29483095)
1. IRAK1 Augments Cancer Stemness and Drug Resistance via the AP-1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma.
Cheng BY; Lau EY; Leung HW; Leung CO; Ho NP; Gurung S; Cheng LK; Lin CH; Lo RC; Ma S; Ng IO; Lee TK
Cancer Res; 2018 May; 78(9):2332-2342. PubMed ID: 29483095
[TBL] [Abstract][Full Text] [Related]
2. Targeting interleukin-1 receptor-associated kinase 1 for human hepatocellular carcinoma.
Li N; Jiang J; Fu J; Yu T; Wang B; Qin W; Xu A; Wu M; Chen Y; Wang H
J Exp Clin Cancer Res; 2016 Sep; 35(1):140. PubMed ID: 27619757
[TBL] [Abstract][Full Text] [Related]
3. BPTF promotes hepatocellular carcinoma growth by modulating hTERT signaling and cancer stem cell traits.
Zhao X; Zheng F; Li Y; Hao J; Tang Z; Tian C; Yang Q; Zhu T; Diao C; Zhang C; Chen M; Hu S; Guo P; Zhang L; Liao Y; Yu W; Chen M; Zou L; Guo W; Deng W
Redox Biol; 2019 Jan; 20():427-441. PubMed ID: 30419422
[TBL] [Abstract][Full Text] [Related]
4. C-terminal truncated hepatitis B virus X protein regulates tumorigenicity, self-renewal and drug resistance via STAT3/Nanog signaling pathway.
Ching RHH; Sze KMF; Lau EYT; Chiu YT; Lee JMF; Ng IOL; Lee TKW
Oncotarget; 2017 Apr; 8(14):23507-23516. PubMed ID: 28186991
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor induces tumour marker AKR1B10 expression through activator protein-1 signalling in hepatocellular carcinoma cells.
Liu Z; Yan R; Al-Salman A; Shen Y; Bu Y; Ma J; Luo DX; Huang C; Jiang Y; Wilber A; Mo YY; Huang MC; Zhao Y; Cao D
Biochem J; 2012 Mar; 442(2):273-82. PubMed ID: 22329800
[TBL] [Abstract][Full Text] [Related]
6. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
[TBL] [Abstract][Full Text] [Related]
7. Regulation of aldo-keto-reductase family 1 B10 by 14-3-3ε and their prognostic impact of hepatocellular carcinoma.
Liu TA; Jan YJ; Ko BS; Wu YJ; Lu YJ; Liang SM; Liu CC; Chen SC; Wang J; Shyue SK; Liou JY
Oncotarget; 2015 Nov; 6(36):38967-82. PubMed ID: 26516929
[TBL] [Abstract][Full Text] [Related]
8. EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma.
Leung HW; Leung CON; Lau EY; Chung KPS; Mok EH; Lei MML; Leung RWH; Tong M; Keng VW; Ma C; Zhao Q; Ng IOL; Ma S; Lee TK
Cancer Res; 2021 Jun; 81(12):3229-3240. PubMed ID: 33903122
[TBL] [Abstract][Full Text] [Related]
9. NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma.
Leung HW; Lau EYT; Leung CON; Lei MML; Mok EHK; Ma VWS; Cho WCS; Ng IOL; Yun JP; Cai SH; Yu HJ; Ma S; Lee TKW
Cancer Lett; 2020 Apr; 476():48-56. PubMed ID: 32061952
[TBL] [Abstract][Full Text] [Related]
10. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
11. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
12. Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC.
Torres-Mena JE; Salazar-Villegas KN; Sánchez-Rodríguez R; López-Gabiño B; Del Pozo-Yauner L; Arellanes-Robledo J; Villa-Treviño S; Gutiérrez-Nava MA; Pérez-Carreón JI
Dig Dis Sci; 2018 Apr; 63(4):934-944. PubMed ID: 29383608
[TBL] [Abstract][Full Text] [Related]
13. Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-κB-HIF-1α pathway.
Cao L; Fan X; Jing W; Liang Y; Chen R; Liu Y; Zhu M; Jia R; Wang H; Zhang X; Zhang Y; Zhou X; Zhao J; Guo Y
Oncotarget; 2015 Mar; 6(9):6627-40. PubMed ID: 25749383
[TBL] [Abstract][Full Text] [Related]
14. Maintenance of stemness by miR-589-5p in hepatocellular carcinoma cells promotes chemoresistance via STAT3 signaling.
Long J; Jiang C; Liu B; Dai Q; Hua R; Chen C; Zhang B; Li H
Cancer Lett; 2018 Jun; 423():113-126. PubMed ID: 29196128
[TBL] [Abstract][Full Text] [Related]
15. Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma.
Sato S; Genda T; Ichida T; Murata A; Tsuzura H; Narita Y; Kanemitsu Y; Ishikawa S; Kikuchi T; Mori M; Hirano K; Iijima K; Wada R; Nagahara A; Watanabe S
J Gastroenterol Hepatol; 2016 Jul; 31(7):1315-22. PubMed ID: 26758591
[TBL] [Abstract][Full Text] [Related]
16. CXCL11 promotes self-renewal and tumorigenicity of α2δ1
Zhang Y; Zhao W; Li S; Lv M; Yang X; Li M; Zhang Z
Cancer Lett; 2019 May; 449():163-171. PubMed ID: 30771435
[TBL] [Abstract][Full Text] [Related]
17. FSTL1 Secreted by Activated Fibroblasts Promotes Hepatocellular Carcinoma Metastasis and Stemness.
Loh JJ; Li TW; Zhou L; Wong TL; Liu X; Ma VWS; Lo CM; Man K; Lee TK; Ning W; Tong M; Ma S
Cancer Res; 2021 Nov; 81(22):5692-5705. PubMed ID: 34551961
[TBL] [Abstract][Full Text] [Related]
18. Matrix stiffness-mediated effects on stemness characteristics occurring in HCC cells.
You Y; Zheng Q; Dong Y; Xie X; Wang Y; Wu S; Zhang L; Wang Y; Xue T; Wang Z; Chen R; Wang Y; Cui J; Ren Z
Oncotarget; 2016 May; 7(22):32221-31. PubMed ID: 27050147
[TBL] [Abstract][Full Text] [Related]
19. Musashi 2 contributes to the stemness and chemoresistance of liver cancer stem cells via LIN28A activation.
Fang T; Lv H; Wu F; Wang C; Li T; Lv G; Tang L; Guo L; Tang S; Cao D; Wu M; Yang W; Wang H
Cancer Lett; 2017 Jan; 384():50-59. PubMed ID: 27721018
[TBL] [Abstract][Full Text] [Related]
20. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
